534 related articles for article (PubMed ID: 30561539)
1. Controlled Human Malaria Infection of Healthy Adults With Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2.
Dejon-Agobe JC; Ateba-Ngoa U; Lalremruata A; Homoet A; Engelhorn J; Nouatin OP; Edoa JR; Fernandes JF; Esen M; Mouwenda YD; Betouke Ongwe EM; Massinga-Loembe M; Hoffman SL; Sim BKL; Theisen M; Kremsner PG; Adegnika AA; Lell B; Mordmüller B
Clin Infect Dis; 2019 Sep; 69(8):1377-1384. PubMed ID: 30561539
[TBL] [Abstract][Full Text] [Related]
2. Cellular and antibody response in GMZ2-vaccinated Gabonese volunteers in a controlled human malaria infection trial.
Nouatin O; Ibáñez J; Fendel R; Ngoa UA; Lorenz FR; Dejon-Agobé JC; Edoa JR; Flügge J; Brückner S; Esen M; Theisen M; Hoffman SL; Moutairou K; Luty AJF; Lell B; Kremsner PG; Adegnika AA; Mordmüller B
Malar J; 2022 Jun; 21(1):191. PubMed ID: 35715803
[TBL] [Abstract][Full Text] [Related]
3. Effect of immune regulatory pathways after immunization with GMZ2 malaria vaccine candidate in healthy lifelong malaria-exposed adults.
Nouatin O; Ateba Ngoa U; Ibáñez J; Dejon-Agobe JC; Mordmüller B; Edoa JR; Mougeni F; Brückner S; Bouyoukou Hounkpatin A; Esen M; Theisen M; Moutairou K; Hoffman SL; Issifou S; Luty AJF; Loembe MM; Agnandji ST; Lell B; Kremsner PG; Adegnika AA
Vaccine; 2020 Jun; 38(27):4263-4272. PubMed ID: 32386747
[TBL] [Abstract][Full Text] [Related]
4. Exploratory analysis of the effect of helminth infection on the immunogenicity and efficacy of the asexual blood-stage malaria vaccine candidate GMZ2.
Nouatin O; Mengue JB; Dejon-Agobé JC; Fendel R; Ibáñez J; Ngoa UA; Edoa JR; Adégbité BR; Honkpéhédji YJ; Zinsou JF; Hounkpatin AB; Moutairou K; Homoet A; Esen M; Kreidenweiss A; Hoffman SL; Theisen M; Luty AJF; Lell B; Agnandji ST; Mombo-Ngoma G; Ramharter M; Kremsner P; Mordmüller B; Adegnika AA
PLoS Negl Trop Dis; 2021 Jun; 15(6):e0009361. PubMed ID: 34061838
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambaréné, Gabon.
Mordmüller B; Szywon K; Greutelaers B; Esen M; Mewono L; Treut C; Mürbeth RE; Chilengi R; Noor R; Kilama WL; Imoukhuede EB; Imbault N; Leroy O; Theisen M; Jepsen S; Milligan P; Fendel R; Kremsner PG; Issifou S
Vaccine; 2010 Sep; 28(41):6698-703. PubMed ID: 20696154
[TBL] [Abstract][Full Text] [Related]
6. A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children.
Bélard S; Issifou S; Hounkpatin AB; Schaumburg F; Ngoa UA; Esen M; Fendel R; de Salazar PM; Mürbeth RE; Milligan P; Imbault N; Imoukhuede EB; Theisen M; Jepsen S; Noor RA; Okech B; Kremsner PG; Mordmüller B
PLoS One; 2011; 6(7):e22525. PubMed ID: 21829466
[TBL] [Abstract][Full Text] [Related]
7. A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults.
Sklar MJ; Maiolatesi S; Patterson N; Sedegah M; Limbach K; Teneza-Mora N; Chuang I; Hollis-Perry KM; Banania JG; Guzman I; Ganeshan H; Reyes S; Hollingdale MR; Wong M; Lindstrom A; Reyes A; Alcorta Y; Garver L; Bankard K; Belmonte A; Belmonte M; Huang J; Gowda K; Inoue S; Velasco R; Bergmann-Leitner E; Hutter J; Lee T; Adams N; Chaudhury S; Hunt D; Tamminga C; Berrie E; Bellamy D; Bittaye M; Ewer K; Diggs C; Soisson LA; Lawrie A; Hill A; Richie TL; Villasante E; Epstein JE; Duplessis CA
PLoS One; 2021; 16(9):e0256980. PubMed ID: 34495988
[TBL] [Abstract][Full Text] [Related]
8. A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children.
Sirima SB; Mordmüller B; Milligan P; Ngoa UA; Kironde F; Atuguba F; Tiono AB; Issifou S; Kaddumukasa M; Bangre O; Flach C; Christiansen M; Bang P; Chilengi R; Jepsen S; Kremsner PG; Theisen M;
Vaccine; 2016 Aug; 34(38):4536-4542. PubMed ID: 27477844
[TBL] [Abstract][Full Text] [Related]
9. Role of human Pegivirus infections in whole Plasmodium falciparum sporozoite vaccination and controlled human malaria infection in African volunteers.
Tumbo AM; Schindler T; Dangy JP; Orlova-Fink N; Bieri JR; Mpina M; Milando FA; Juma O; Hamad A; Nyakarungu E; Chemba M; Mtoro A; Ramadhan K; Olotu A; Makweba D; Mgaya S; Stuart K; Perreau M; Stapleton JT; Jongo S; Hoffman SL; Tanner M; Abdulla S; Daubenberger C
Virol J; 2021 Jan; 18(1):28. PubMed ID: 33499880
[TBL] [Abstract][Full Text] [Related]
10. Safety, Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of
Jongo SA; Shekalaghe SA; Church LWP; Ruben AJ; Schindler T; Zenklusen I; Rutishauser T; Rothen J; Tumbo A; Mkindi C; Mpina M; Mtoro AT; Ishizuka AS; Kassim KR; Milando FA; Qassim M; Juma OA; Mwakasungula S; Simon B; James ER; Abebe Y; Kc N; Chakravarty S; Saverino E; Bakari BM; Billingsley PF; Seder RA; Daubenberger C; Sim BKL; Richie TL; Tanner M; Abdulla S; Hoffman SL
Am J Trop Med Hyg; 2018 Aug; 99(2):338-349. PubMed ID: 29943719
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial.
Sissoko MS; Healy SA; Katile A; Zaidi I; Hu Z; Kamate B; Samake Y; Sissoko K; Mwakingwe-Omari A; Lane J; Imeru A; Mohan R; Thera I; Guindo CO; Dolo A; Niare K; Koïta F; Niangaly A; Rausch KM; Zeguime A; Guindo MA; Bah A; Abebe Y; James ER; Manoj A; Murshedkar T; Kc N; Sim BKL; Billingsley PF; Richie TL; Hoffman SL; Doumbo O; Duffy PE
Lancet Infect Dis; 2022 Mar; 22(3):377-389. PubMed ID: 34801112
[TBL] [Abstract][Full Text] [Related]
12. Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01.
Payne RO; Milne KH; Elias SC; Edwards NJ; Douglas AD; Brown RE; Silk SE; Biswas S; Miura K; Roberts R; Rampling TW; Venkatraman N; Hodgson SH; Labbé GM; Halstead FD; Poulton ID; Nugent FL; de Graaf H; Sukhtankar P; Williams NC; Ockenhouse CF; Kathcart AK; Qabar AN; Waters NC; Soisson LA; Birkett AJ; Cooke GS; Faust SN; Woods C; Ivinson K; McCarthy JS; Diggs CL; Vekemans J; Long CA; Hill AV; Lawrie AM; Dutta S; Draper SJ
J Infect Dis; 2016 Jun; 213(11):1743-51. PubMed ID: 26908756
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.
Sirima SB; Durier C; Kara L; Houard S; Gansane A; Loulergue P; Bahuaud M; Benhamouda N; Nebié I; Faber B; Remarque E; Launay O;
Vaccine; 2017 Oct; 35(45):6218-6227. PubMed ID: 28947345
[TBL] [Abstract][Full Text] [Related]
14. Effect of hookworm infection and anthelmintic treatment on naturally acquired antibody responses against the GMZ2 malaria vaccine candidate and constituent antigens.
Amoani B; Gyan B; Sakyi SA; Abu EK; Nuvor SV; Barnes P; Sarkodie-Addo T; Ahenkorah B; Sewor C; Dwomoh D; Theisen M; Cappello M; Wilson MD; Adu B
BMC Infect Dis; 2021 Apr; 21(1):332. PubMed ID: 33832450
[TBL] [Abstract][Full Text] [Related]
15. A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-naïve adults.
Cummings JF; Polhemus ME; Kester KE; Ockenhouse CF; Gasser RA; Coyne P; Wortmann G; Nielsen RK; Schaecher K; Holland CA; Krzych U; Tornieporth N; Soisson LA; Angov E; Heppner DG;
Vaccine; 2024 Apr; 42(12):3066-3074. PubMed ID: 38584058
[TBL] [Abstract][Full Text] [Related]
16. The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria endemic and non-endemic areas.
Jepsen MP; Jogdand PS; Singh SK; Esen M; Christiansen M; Issifou S; Hounkpatin AB; Ateba-Ngoa U; Kremsner PG; Dziegiel MH; Olesen-Larsen S; Jepsen S; Mordmüller B; Theisen M
J Infect Dis; 2013 Aug; 208(3):479-88. PubMed ID: 23624363
[TBL] [Abstract][Full Text] [Related]
17. PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection.
Murphy SC; Deye GA; Sim BKL; Galbiati S; Kennedy JK; Cohen KW; Chakravarty S; Kc N; Abebe Y; James ER; Kublin JG; Hoffman SL; Richie TL; Jackson LA
PLoS Pathog; 2021 May; 17(5):e1009594. PubMed ID: 34048504
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.
Tamborrini M; Stoffel SA; Westerfeld N; Amacker M; Theisen M; Zurbriggen R; Pluschke G
Malar J; 2011 Dec; 10():359. PubMed ID: 22166048
[TBL] [Abstract][Full Text] [Related]
19. Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection.
Lyke KE; Ishizuka AS; Berry AA; Chakravarty S; DeZure A; Enama ME; James ER; Billingsley PF; Gunasekera A; Manoj A; Li M; Ruben AJ; Li T; Eappen AG; Stafford RE; Kc N; Murshedkar T; Mendoza FH; Gordon IJ; Zephir KL; Holman LA; Plummer SH; Hendel CS; Novik L; Costner PJ; Saunders JG; Berkowitz NM; Flynn BJ; Nason MC; Garver LS; Laurens MB; Plowe CV; Richie TL; Graham BS; Roederer M; Sim BK; Ledgerwood JE; Hoffman SL; Seder RA
Proc Natl Acad Sci U S A; 2017 Mar; 114(10):2711-2716. PubMed ID: 28223498
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and Protective Efficacy of Radiation-Attenuated and Chemo-Attenuated PfSPZ Vaccines in Equatoguinean Adults.
Jongo SA; Urbano V; Church LWP; Olotu A; Manock SR; Schindler T; Mtoro A; Kc N; Hamad A; Nyakarungu E; Mpina M; Deal A; Bijeri JR; Ondo Mangue ME; Ntutumu Pasialo BE; Nguema GN; Owono SN; Rivas MR; Chemba M; Kassim KR; James ER; Stabler TC; Abebe Y; Saverino E; Sax J; Hosch S; Tumbo AM; Gondwe L; Segura JL; Falla CC; Phiri WP; Hergott DEB; García GA; Schwabe C; Maas CD; Murshedkar T; Billingsley PF; Tanner M; Ayekaba MO; Sim BKL; Daubenberger C; Richie TL; Abdulla S; Hoffman SL
Am J Trop Med Hyg; 2021 Jan; 104(1):283-293. PubMed ID: 33205741
[No Abstract] [Full Text] [Related]
[Next] [New Search]
